A Phase 3, Randomized, Open-Label Study of Lorlatinib (PF-06463922) Monotherapy versus Crizotinib Monotherapy in the First-Line Treatment of Patients with Advanced ALK-positive NSCLC. Here, ALK is linked to non-small cell lung carcinoma.